SPF45/RBM17-dependent splicing and multidrug resistance to cancer chemotherapy

Kazuhiro Fukumura; Julian P Venables; Akila Mayeda

doi:10.1080/23723556.2021.1996318

SPF45/RBM17-dependent splicing and multidrug resistance to cancer chemotherapy

Mol Cell Oncol. 2021 Nov 15;8(6):1996318. doi: 10.1080/23723556.2021.1996318. eCollection 2021.

Authors

Kazuhiro Fukumura¹, Julian P Venables², Akila Mayeda¹

Affiliations

¹ Division of Gene Expression Mechanism, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Aichi, Japan.
² Science Sense, 2 Rue St Vincent, Salèlles du Bosc, 34700 Le Bosc, France.

Abstract

The early splicing complex A occupies at least eighty nucleotides of intron, in which U2AF covers the polypyrimidine tract. SPF45 (RBM17) functionally substitutes for U2AF on a subset of short introns. Since SPF45 expression confers resistance to various anticancer drugs, SPF45-dependent splicing may play a critical role in multidrug resistance.

Keywords: Pre-mRNA splicing; SPF45 (RBM17); U2AF heterodimer; anticancer drug resistance; short intron.

Grants and funding

K.F. was partly supported by Grants-in-Aid for Scientific Research (C) [Grant number: JP18K07304] from the Japan Society for the Promotion of Science (JSPS), a Research Grant from the Hori Sciences and Arts Foundation, and a Research Grant from Nitto Foundation. A.M. was partly supported by Grants-in-Aid for Scientific Research (B) [Grant number: JP16H04705] and for Challenging Exploratory Research [Grant number: JP16K14659] from JSPS.